Clinical application of the PFA-100® : Current Opinion in Hematology (original) (raw)
Hemostasis and thrombosis
Diagnostic Haemostasis Laboratory, Department of Hematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Western Sydney Area Health Service, Westmead, NSW, Australia.
Correspondence to Dr. E. J. Favaloro, Department of Hematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, WSAHS, WESTMEAD, NSW, 2145, AUSTRALIA; e-mail: [email protected]
Abstract
The PFA-100® (platelet function analyzer) is a relatively new tool for the investigation of primary hemostasis. Recent studies have shown its utility as a screening tool for investigating possible von Willebrand disorder (VWD) and various platelet disorders. More recently, the PFA-100® has been shown to be valuable in monitoring desmopressin acetate (DDAVP) therapy in both VWD and platelet disorders. The PFA-100® has also been evaluated in many other studies for its utility in assessing drug effects, for potential monitoring of antiplatelet medication (including aspirin), or for evaluation of overall primary hemostasis in various clinical disorders or during surgical procedures. This article reviews current findings and highlights the benefits and limitations of the clinical utility of the PFA-100®. Ultimately, the greatest strengths of the PFA-100® are its simplicity of use and excellent sensitivity to particular hemostatic disturbances such as VWD, platelet disorders, and platelet-affecting medication. However, because it is thus a global test system, this also creates a significant limitation because the PFA-100® is not specific for, nor predictive of, any particular disorder. However, used appropriately, the PFA-100® can be considered a worthwhile addition to any hemostasis laboratory involved in the diagnosis or therapeutic monitoring of bleeding disorders and potentially of antiplatelet medication. This review should be valuable to both hemostasis scientists and clinical specialists.
© 2002 Lippincott Williams & Wilkins, Inc.